Medindia

X

Novartis Receives FDA Approval of Menveo(R), a Vaccine to Prevent Meningococcal Disease

Monday, February 22, 2010 Drug News J E 4
Advertisement
- Menveo licensed in 11-55 year olds to help protect against potentially deadly meningitis and sepsis caused by four common vaccine-preventable serogroups(1)

Central phone:

+41 61 324 7944

Ruth Metzler-Arnold

+41 61 324 9980

North America:

Pierre-Michel Bringer

+41 61 324 1065

Richard Jarvis

+1 212 830 2433

John Gilardi

+41 61 324 3018

Jill Pozarek

+1 212 830 2445

Thomas Hungerbuehler

+41 61 324 8425

Edwin Valeriano

+1 212 830 2456

Isabella Zinck

+41 61 324 7188

e-mail: investor.relations@novartis.com

e-mail: investor.relations@novartis.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CIPA Named Google's Canadian Online Pharmacy Verif...
S
AppDynamics Announces General Availability of AppD...